| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation
¶
From the Departments of Pathology,* Urology, and Biostatistics,¶ and the Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan; and the Departments of Pathology and Urology, Faculty of Medicine, University of Ulm, Ulm, Germany
-Methylacyl-CoA racemase (AMACR) has previously been shown to be a highly sensitive marker for colorectal and clinically localized prostate cancer (PCa). However, AMACR expression was down-regulated at the transcript and protein level in hormone-refractory metastatic PCa, suggesting a hormone-dependent expression of AMACR. To further explore the hypothesis that AMACR is hormone regulated and plays a role in PCa progression AMACR protein expression was characterized in a broad range of PCa samples treated with variable amounts and lengths of exogenous anti-androgens. Analysis included standard slides and high-density tissue microarrays. AMACR protein expression was significantly increased in localized hormone-naive PCa as compared to benign (P < 0.001). Mean AMACR expression was lower in tissue samples from patients who had received neoadjuvant hormone treatment but still higher compared to hormone-refractory metastases. The hormone-sensitive tumor cell line, LNCaP, demonstrated stronger AMACR expression by Western blot analysis than the poorly differentiated cell lines DU-145 and PC-3. AMACR protein expression in cells after exposure to anti-androgen treatment was unchanged, whereas prostate-specific antigen, known to be androgen-regulated, demonstrated decreased protein expression. Surprisingly, this data suggests that AMACR expression is not regulated by androgens. Examination of colorectal cancer, which is not hormone regulated, demonstrated high levels of AMACR expression in well to moderately differentiated tumors and weak expression in anaplastic colorectal cancers. Taken together, these data suggest that AMACR expression is not hormone-dependent but may in fact be a marker of tumor differentiation.
This article has been cited by other articles:
 |
|
 |
|
  C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Witkiewicz, S. Varambally, R. Shen, R. Mehra, M. S. Sabel, D. Ghosh, A. M. Chinnaiyan, M. A. Rubin, and C. G. Kleer {alpha}-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1418 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rubin, T. A. Bismar, O. Andren, L. Mucci, R. Kim, R. Shen, D. Ghosh, J. T. Wei, A. M. Chinnaiyan, H.-O. Adami, et al. Decreased {alpha}-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1424 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Gu, M. A. Rubin, Y. Yang, S. E. Deprimo, H. Zhao, S. Horvath, J. D. Brooks, M. Loda, and R. E. Reiter Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer Clin. Cancer Res., March 15, 2005; 11(6): 2237 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Shah, R. Mehra, A. M. Chinnaiyan, R. Shen, D. Ghosh, M. Zhou, G. R. MacVicar, S. Varambally, J. Harwood, T. A. Bismar, et al. Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases: Lessons from a Rapid Autopsy Program Cancer Res., December 15, 2004; 64(24): 9209 - 9216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G.J. van Breda, E. van Agen, L. G.J.B. Engels, E. J.C. Moonen, J. C.S. Kleinjans, and J. H.M. van Delft Altered vegetable intake affects pivotal carcinogenesis pathways in colon mucosa from adenoma patients and controls Carcinogenesis, November 1, 2004; 25(11): 2207 - 2216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kumar-Sinha, R. B. Shah, B. Laxman, S. A. Tomlins, J. Harwood, W. Schmitz, E. Conzelmann, M. G. Sanda, J. T. Wei, M. A. Rubin, et al. Elevated {alpha}-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer Am. J. Pathol., March 1, 2004; 164(3): 787 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rubin, M. P. Zerkowski, R. L. Camp, R. Kuefer, M. D. Hofer, A. M. Chinnaiyan, and D. L. Rimm Quantitative Determination of Expression of the Prostate Cancer Protein {alpha}-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA): A Novel Paradigm for Automated and Continuous Biomarker Measurements Am. J. Pathol., March 1, 2004; 164(3): 831 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A J Evans {alpha}-Methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies J. Clin. Pathol., December 1, 2003; 56(12): 892 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zha, S. Ferdinandusse, S. Denis, R. J. Wanders, C. M. Ewing, J. Luo, A. M. De Marzo, and W. B. Isaacs {alpha}-Methylacyl-CoA Racemase as an Androgen-Independent Growth Modifier in Prostate Cancer Cancer Res., November 1, 2003; 63(21): 7365 - 7376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Mobley, I. Leav, P. Zielie, C. Wotkowitz, J. Evans, Y.-W. Lam, B. S. L'Esperance, Z. Jiang, and S.-M. Ho Branched Fatty Acids in Dairy and Beef Products Markedly Enhance {alpha}-Methylacyl-CoA Racemase Expression in Prostate Cancer Cells in Vitro Cancer Epidemiol. Biomarkers Prev., August 1, 2003; 12(8): 775 - 783. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
